Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Floretyrosine F 18→

Floretyrosine F 18 Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
178433-03-9
Molecular formula
C11H14[18F]NO3
Molecular weight
226.238 g/mol
Drug class
18F-labelled amino-acid PET radiotracerdiagnostic imaging agent
Mechanism of action
Radiolabelled fluoroethyltyrosine is transported into cells by large neutral amino acid transporters (LAT1/LAT2). Increased uptake in metabolically active tumour tissue can support PET imaging; it is a diagnostic radiopharmaceutical, not a therapeutic tyrosine analogue.
Indications / reported uses
  • PET imaging of brain tumours in adults with cognitive impairment or suspected glioma to assist assessment of amino-acid transport and tumour activity under the specific radiopharmaceutical product authorisation; the exact intended use is jurisdiction- and product-specific

Sources: PubMed — 18F-fluoroethyltyrosine PET imaging · NLM MeSH — Fluoroethyltyrosine F18 · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

18F-labelled amino-acid PET radiotracer; diagnostic imaging agent

Mechanism of action

Radiolabelled fluoroethyltyrosine is transported into cells by large neutral amino acid transporters (LAT1/LAT2). Increased uptake in metabolically active tumour tissue can support PET imaging; it is a diagnostic radiopharmaceutical, not a therapeutic tyrosine analogue.

General use cases

  • PET imaging of brain tumours in adults with cognitive impairment or suspected glioma to assist assessment of amino-acid transport and tumour activity under the specific radiopharmaceutical product authorisation; the exact intended use is jurisdiction- and product-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Floretyrosine F 18 Environmental Risk Assessment (ERA) (the Floretyrosine F 18 ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.